SDHA
Basic information
Region (hg38): 5:218303-257082
Previous symbols: [ "SDH2" ]
Links
Phenotypes
GenCC
Source:
- Leigh syndrome (Definitive), mode of inheritance: AR
- paragangliomas 5 (Moderate), mode of inheritance: AD
- Leigh syndrome (Moderate), mode of inheritance: AR
- familial isolated dilated cardiomyopathy (Supportive), mode of inheritance: AD
- mitochondrial complex II deficiency (Supportive), mode of inheritance: AR
- hereditary pheochromocytoma-paraganglioma (Supportive), mode of inheritance: AD
- gastrointestinal stromal tumor (Supportive), mode of inheritance: AD
- Leigh syndrome with leukodystrophy (Supportive), mode of inheritance: AR
- paragangliomas 5 (Definitive), mode of inheritance: AD
- mitochondrial complex II deficiency, nuclear type 1 (Strong), mode of inheritance: AR
- neurodegeneration with ataxia and late-onset optic atrophy (Strong), mode of inheritance: AD
- paragangliomas 5 (Strong), mode of inheritance: AD
- hereditary pheochromocytoma-paraganglioma (Definitive), mode of inheritance: AD
- Leigh syndrome (Moderate), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Pheochromocytoma/paraganglioma syndrome 5; Gastrointestinal stromal tumors; Cardiomyopathy, dilated, 1GG; Neurodegeneration with ataxia and late-onset optic atrophy; Mitochondrial respiratory chain complex II deficiency, nuclear type 1 | AD/AR | Biochemical; Cardiovascular; Gastrointestinal; Oncologic | For conditions that involve increased risk of neoplasms, awareness and surveillance may allow early diagnosis and treatment (eg, via surgical management), which may improve outcomes; In conditions such as Cardiomyopathy, dilated, Neurodegeneration with ataxia and late-onset optic atrophy; and Mitochondrial respiratory chain complex II deficiency, nuclear type 1, recognition of cardiovascular disease may allow early medical management, which may be helpful to help decrease morbidity; In Mitochondrial respiratory chain complex II deficiency, medical treatment (eg, with riboflavin, ubiquinol) may be beneficial, and individuals may have cardiac involvement such that surveillance may be beneficial | Biochemical; Cardiovascular; Musculoskeletal; Neurologic; Oncologic | 7550341; 8967754; 10746566; 10976639; 12794685; 16737791; 16798039; 20484225; 20551992; 21505157; 22972948; 23322652; 27683074 |
ClinVar
This is a list of variants' phenotypes submitted to
- Hereditary cancer-predisposing syndrome (58 variants)
- Mitochondrial complex II deficiency, nuclear type 1;Paragangliomas 5 (56 variants)
- Paragangliomas 5 (42 variants)
- Paragangliomas 5;Mitochondrial complex II deficiency, nuclear type 1 (40 variants)
- not provided (9 variants)
- Dilated cardiomyopathy 1GG (6 variants)
- Gastrointestinal stromal tumor (4 variants)
- Mitochondrial complex II deficiency, nuclear type 1 (3 variants)
- Pheochromocytoma (1 variants)
- Hereditary pheochromocytoma-paraganglioma;Gastrointestinal stromal tumor;Mitochondrial complex II deficiency, nuclear type 1;Paragangliomas 5 (1 variants)
- Neurodegeneration with ataxia and late-onset optic atrophy (1 variants)
- Hereditary pheochromocytoma-paraganglioma (1 variants)
- Dilated cardiomyopathy 1GG;Neurodegeneration with ataxia and late-onset optic atrophy;Mitochondrial complex II deficiency, nuclear type 1;Paragangliomas 5 (1 variants)
- SDHA-related disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SDHA gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 549 | 563 | ||||
missense | 1249 | 1263 | ||||
nonsense | 48 | 57 | ||||
start loss | 10 | |||||
frameshift | 77 | 32 | 117 | |||
inframe indel | 20 | 20 | ||||
splice donor/acceptor (+/-2bp) | 52 | 60 | ||||
splice region | 1 | 77 | 87 | 4 | 169 | |
non coding | 38 | 213 | 18 | 270 | ||
Total | 136 | 104 | 1326 | 768 | 26 |
Highest pathogenic variant AF is 0.0000263
Variants in SDHA
This is a list of pathogenic ClinVar variants found in the SDHA region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
5-218320-A-AGGGACTGGC | Paragangliomas 5 | Benign (Nov 06, 2023) | ||
5-218349-A-C | Paragangliomas 5 • not specified • Mitochondrial complex II deficiency, nuclear type 1;Paragangliomas 5 • Mitochondrial complex II deficiency, nuclear type 1 • Hereditary pheochromocytoma-paraganglioma • Leigh syndrome • Hereditary cancer-predisposing syndrome | Conflicting classifications of pathogenicity (Nov 01, 2024) | ||
5-218350-G-A | Uncertain significance (Nov 07, 2023) | |||
5-218351-C-G | Hereditary cancer-predisposing syndrome | Uncertain significance (Feb 01, 2024) | ||
5-218351-C-T | Paragangliomas 5 • Hereditary cancer-predisposing syndrome | Uncertain significance (Jul 15, 2023) | ||
5-218351-C-CA | Hereditary cancer-predisposing syndrome | Uncertain significance (Jan 04, 2017) | ||
5-218352-A-C | Hereditary cancer-predisposing syndrome | Uncertain significance (Feb 18, 2021) | ||
5-218352-A-G | not specified • Leigh syndrome • Hereditary pheochromocytoma-paraganglioma • Mitochondrial complex II deficiency, nuclear type 1 • Hereditary cancer-predisposing syndrome | Benign/Likely benign (Apr 14, 2021) | ||
5-218352-A-T | Hereditary cancer-predisposing syndrome | Uncertain significance (Jul 29, 2020) | ||
5-218353-G-A | Hereditary cancer-predisposing syndrome | Uncertain significance (Mar 08, 2022) | ||
5-218353-G-C | Hereditary cancer-predisposing syndrome | Uncertain significance (Dec 09, 2022) | ||
5-218353-G-T | Hereditary cancer-predisposing syndrome | Uncertain significance (Jul 11, 2023) | ||
5-218354-A-G | Hereditary cancer-predisposing syndrome | Uncertain significance (Nov 14, 2023) | ||
5-218354-A-T | Hereditary cancer-predisposing syndrome • Mitochondrial complex II deficiency, nuclear type 1 • Hereditary pheochromocytoma-paraganglioma • Leigh syndrome | Conflicting classifications of pathogenicity (May 03, 2024) | ||
5-218354-AC-A | Hereditary cancer-predisposing syndrome | Uncertain significance (Feb 05, 2021) | ||
5-218355-C-G | Hereditary cancer-predisposing syndrome | Uncertain significance (Jan 31, 2024) | ||
5-218355-C-T | Leigh syndrome • Mitochondrial complex II deficiency, nuclear type 1 • Hereditary pheochromocytoma-paraganglioma • Hereditary cancer-predisposing syndrome | Conflicting classifications of pathogenicity (Jan 09, 2024) | ||
5-218355-CA-C | Mitochondrial complex II deficiency, nuclear type 1;Paragangliomas 5 | Pathogenic (Aug 17, 2023) | ||
5-218356-A-C | Mitochondrial complex II deficiency, nuclear type 1 • Mitochondrial complex II deficiency, nuclear type 1;Paragangliomas 5 • Hereditary cancer-predisposing syndrome • Paragangliomas 5 • Neurodegeneration with ataxia and late-onset optic atrophy | Pathogenic (Nov 19, 2023) | ||
5-218356-A-G | Mitochondrial complex II deficiency, nuclear type 1;Paragangliomas 5 • Hereditary cancer-predisposing syndrome • Paragangliomas 5 | Pathogenic/Likely pathogenic (Feb 06, 2024) | ||
5-218356-A-T | Paragangliomas 5 • Paragangliomas 5;Mitochondrial complex II deficiency, nuclear type 1 • Hereditary cancer-predisposing syndrome | Pathogenic/Likely pathogenic (Dec 30, 2023) | ||
5-218357-T-A | Mitochondrial complex II deficiency, nuclear type 1;Paragangliomas 5 • Hereditary cancer-predisposing syndrome • Paragangliomas 5 | Pathogenic (Nov 24, 2023) | ||
5-218357-T-C | Mitochondrial complex II deficiency, nuclear type 1;Paragangliomas 5 • Paragangliomas 5 • Hereditary cancer-predisposing syndrome | Pathogenic/Likely pathogenic (Dec 05, 2023) | ||
5-218357-T-G | Paragangliomas 5;Mitochondrial complex II deficiency, nuclear type 1 • Rhabdomyosarcoma • Hereditary cancer-predisposing syndrome • Paragangliomas 5 • Dilated cardiomyopathy 1GG;Neurodegeneration with ataxia and late-onset optic atrophy;Paragangliomas 5;Mitochondrial complex II deficiency, nuclear type 1 | Pathogenic/Likely pathogenic (Feb 06, 2024) | ||
5-218356-A-ATGTCGGGGGTCCGGGGCC | Mitochondrial complex II deficiency, nuclear type 1;Paragangliomas 5 | Uncertain significance (May 03, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SDHA | protein_coding | protein_coding | ENST00000264932 | 15 | 38460 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
2.61e-10 | 0.972 | 125631 | 0 | 117 | 125748 | 0.000465 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.745 | 346 | 387 | 0.893 | 0.0000260 | 4262 |
Missense in Polyphen | 139 | 179.81 | 0.77303 | 1899 | ||
Synonymous | -1.41 | 184 | 161 | 1.14 | 0.0000122 | 1339 |
Loss of Function | 2.22 | 21 | 35.2 | 0.596 | 0.00000219 | 385 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000664 | 0.000658 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.000185 | 0.000185 |
European (Non-Finnish) | 0.000749 | 0.000747 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.000327 | 0.000294 |
Other | 0.000326 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Flavoprotein (FP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q) (PubMed:24781757). Can act as a tumor suppressor (PubMed:20484225). {ECO:0000269|PubMed:20484225, ECO:0000305|PubMed:24781757}.;
- Disease
- DISEASE: Mitochondrial complex II deficiency (MT-C2D) [MIM:252011]: A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations. Clinical features include psychomotor regression in infants, poor growth with lack of speech development, severe spastic quadriplegia, dystonia, progressive leukoencephalopathy, muscle weakness, exercise intolerance, cardiomyopathy. Some patients manifest Leigh syndrome or Kearns-Sayre syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry. {ECO:0000269|PubMed:12794685}.; DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:10746566, ECO:0000269|PubMed:24781757, ECO:0000269|PubMed:7550341}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, dilated 1GG (CMD1GG) [MIM:613642]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:20551992}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Paragangliomas 5 (PGL5) [MIM:614165]: A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion. Paragangliomas can develop at various body sites, including the head, neck, thorax and abdomen. Most commonly, they are located in the head and neck region, specifically at the carotid bifurcation, the jugular foramen, the vagal nerve, and in the middle ear. {ECO:0000269|PubMed:20484225}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Citrate cycle (TCA cycle) - Homo sapiens (human);Non-alcoholic fatty liver disease (NAFLD) - Homo sapiens (human);Alzheimer,s disease - Homo sapiens (human);Huntington,s disease - Homo sapiens (human);Thermogenesis - Homo sapiens (human);Oxidative phosphorylation - Homo sapiens (human);Parkinson,s disease - Homo sapiens (human);Warburg Effect;Mitochondrial Electron Transport Chain;The oncogenic action of Succinate;The oncogenic action of Fumarate;Pyruvate dehydrogenase deficiency (E3);Pyruvate dehydrogenase deficiency (E2);2-ketoglutarate dehydrogenase complex deficiency;Mitochondrial complex II deficiency;Fumarase deficiency;Congenital lactic acidosis;Citric Acid Cycle;Glutaminolysis and Cancer;The oncogenic action of 2-hydroxyglutarate;The oncogenic action of L-2-hydroxyglutarate in Hydroxygluaricaciduria;The oncogenic action of D-2-hydroxyglutarate in Hydroxygluaricaciduria ;Electron Transport Chain;TCA Cycle and Deficiency of Pyruvate Dehydrogenase complex (PDHc);fig-met-1-last-solution;Amino Acid metabolism;TCA Cycle;Citrate cycle;Citric acid cycle (TCA cycle);Pyruvate metabolism and Citric Acid (TCA) cycle;Respiratory electron transport;The citric acid (TCA) cycle and respiratory electron transport;Metabolism;TCA cycle;TCA cycle;Arginine Proline metabolism;superpathway of conversion of glucose to acetyl CoA and entry into the TCA cycle;Tyrosine metabolism;Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.
(Consensus)
Intolerance Scores
- loftool
- 0.432
- rvis_EVS
- -0.86
- rvis_percentile_EVS
- 10.95
Haploinsufficiency Scores
- pHI
- 0.296
- hipred
- Y
- hipred_score
- 0.590
- ghis
- 0.497
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.983
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Sdha
- Phenotype
- homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Gene ontology
- Biological process
- tricarboxylic acid cycle;succinate metabolic process;mitochondrial electron transport, succinate to ubiquinone;nervous system development;respiratory electron transport chain;oxidation-reduction process
- Cellular component
- nucleolus;mitochondrion;mitochondrial inner membrane;mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone);myelin sheath;plasma membrane succinate dehydrogenase complex
- Molecular function
- succinate dehydrogenase activity;protein binding;succinate dehydrogenase (ubiquinone) activity;electron transfer activity;flavin adenine dinucleotide binding